Combinations ; See Below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Invirase | Roche | Roche Products | 200mg | 270 | Capsule | per capsule | KES 12,521.00 |
| Invirase | Roche | Roche Products | 500mg | 120 | Tablet | per tablet | KES 11,653.00 |
| Saquinavir more info | |
|---|---|
| Mode Of Action | Protease inhibitors (PI) Inhibits HIV proteases, preventing viral maturation and replication |
| Drug Indication | HIV (in combination with other ARVs). It is infrequently used as a sole PI due to its poor absorption profile. |
| Precautions | Monitoring of aminotranferases, cholesterol and triglycerides preferably on bi-monthly basis; it is metabolized in the liver hence its dose reduced in serious hepatic impairment. |
| Contra-Indications | Predisposition to cardiac arrhythmias (including congenital QT prolongation, bradycardia, history of symptomatic arrhythmias, heart failure with reduced left ventricular ejection fraction, electrolyte disturbances, concomitant use of drugs that prolong QT or PR interval); concomitant use of drugs that increase plasma-saquinavir concentration (avoid unless no alternative treatment available), efavirenz; rifampicin and amiodarone. |
| Side Effects | Abdominal pain; flatulence; dry eyes; cough; oral ulcers and general weakness. |
| Dosage | 600mg TID. Taken with food. |
| Pregnancy Category | Category B1 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals have not shown evidence of an increased occurrence of foetal damage. |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Hiv Chemotherapy |